Published in J Theor Biol on November 07, 2002
Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART. BMC Infect Dis (2008) 1.15
How many human immunodeficiency virus type 1-infected target cells can a cytotoxic T-lymphocyte kill? J Virol (2005) 1.07
Predicting the impact of blocking human immunodeficiency virus type 1 Nef in vivo. J Virol (2008) 0.79
Biologically-directed modeling reflects cytolytic clearance of SIV-infected cells in vivo in macaques. PLoS One (2012) 0.78
On modeling HIV and T cells in vivo: assessing causal estimators in vaccine trials. PLoS Comput Biol (2006) 0.78
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet (2008) 8.37
Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors. Immunity (2004) 6.89
Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst (2002) 5.57
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis (2005) 5.14
A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis (2007) 3.95
Neonatal innate TLR-mediated responses are distinct from those of adults. J Immunol (2009) 3.29
Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One (2008) 3.05
Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine (2006) 2.89
Denoising array-based comparative genomic hybridization data using wavelets. Biostatistics (2005) 2.56
Evaluating a surrogate endpoint at three levels, with application to vaccine development. Stat Med (2008) 2.50
Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection. J Virol (2010) 2.02
On the analysis of viral load endpoints in HIV vaccine trials. Stat Med (2003) 1.89
Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials. J Immunol Methods (2006) 1.76
Ontogeny of Toll-like receptor mediated cytokine responses of human blood mononuclear cells. PLoS One (2010) 1.66
Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments. J Infect Dis (2009) 1.58
Development of an automated analysis system for data from flow cytometric intracellular cytokine staining assays from clinical vaccine trials. Cytometry A (2008) 1.54
What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials. J Infect Dis (2003) 1.38
Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trials. J Immunol Methods (2004) 1.37
The clustering of regression models method with applications in gene expression data. Biometrics (2006) 1.32
Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagus. Cancer Prev Res (Phila) (2013) 1.31
Equivalence of ELISpot assays demonstrated between major HIV network laboratories. PLoS One (2010) 1.30
Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study. PLoS One (2011) 1.16
Chromosomal instability in Barrett's esophagus is related to telomere shortening. Cancer Epidemiol Biomarkers Prev (2006) 1.12
How many human immunodeficiency virus type 1-infected target cells can a cytotoxic T-lymphocyte kill? J Virol (2005) 1.07
Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys. J Virol (2009) 1.06
A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens. Stat Commun Infect Dis (2011) 1.06
Direct inference of SNP heterozygosity rates and resolution of LOH detection. PLoS Comput Biol (2007) 1.06
Advancing the high throughput identification of liver fibrosis protein signatures using multiplexed ion mobility spectrometry. Mol Cell Proteomics (2014) 1.04
Response to Andrew Dunning's comment on 'evaluating a surrogate endpoint at three levels, with application to vaccine development'. Stat Med (2009) 0.94
HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1. PLoS Pathog (2013) 0.90
Towards prediction of degenerate CTL epitope recognition. Hum Vaccin (2007) 0.89
Statistical evaluation of HIV vaccines in early clinical trials. Contemp Clin Trials (2006) 0.86
Focus and breadth of cellular immune responses elicited by a heterologous insert prime-boost vaccine regimen in rhesus monkeys. Vaccine (2011) 0.85
Do scarce targets or T killers control primary HIV infection? J Theor Biol (2002) 0.85
Finding gene clusters for a replicated time course study. BMC Res Notes (2014) 0.83
Endpoints in vaccine trials. Stat Methods Med Res (2004) 0.82
HIV fragment gag vaccine induces broader T cell response in mice. Vaccine (2011) 0.81
[Randomized trial of breast self-examination in 266,064 women in Shanghai]. Zhonghua Zhong Liu Za Zhi (2005) 0.79
On modeling HIV and T cells in vivo: assessing causal estimators in vaccine trials. PLoS Comput Biol (2006) 0.78
On simulating strongly interacting, stochastic population models. II. Multiple compartments. Math Biosci (2004) 0.78
Identifying trait clusters by linkage profiles: application in genetical genomics. Bioinformatics (2008) 0.77
On simulating strongly-interacting, stochastic population models. Math Biosci (2004) 0.76
A Comparison of Testing Parameters and the Implementation of a Group Sequential Design for Equivalence Studies Using Paired-sample Analysis. Stat Biopharm Res (2012) 0.75